EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetesIn VivoEP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal/nrate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:Caspase. Molecular Formula: C18H23FN2O6 Molecular Weight: 382.38 PubChem CID: 9907987 Isomeric SMILES: CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)CF)NC(=O)OCC1=CC=CC=C1
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 1.06 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- E647027-10mg
- CAS:
- 223568-55-6
- Product Size:
- 10mg
